Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $8.80, for a total value of $44,000.00. Following the completion of the transaction, the chief technology officer owned 172,171 shares of the company’s stock, valued at approximately $1,515,104.80. The trade was a 2.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.60, for a total transaction of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total transaction of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Up 4.6%

NASDAQ:SOPH opened at $8.92 on Friday. The firm has a market capitalization of $748.34 million, a P/E ratio of -7.76 and a beta of 0.96. SOPHiA GENETICS SA has a 1-year low of $3.10 and a 1-year high of $8.98. The company’s fifty day moving average price is $6.46 and its 200-day moving average price is $5.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth approximately $9,809,000. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Archon Capital Management LLC raised its stake in SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Unusual trading volume is drawing attention to SOPH, with the stock approaching a new 12-month high. The activity suggests increased investor interest and reinforces the recent upward momentum. When Unusual Volume Isn’t Noise: 3 Small-Caps Sending Signals
• Positive Sentiment: Analyst sentiment improved after the August 5 earnings report. BTIG Research raised its price target to $9 from $8, while HC Wainwright lifted its target to $14 from $12; both firms maintained Buy ratings. The reported $23.31 million in revenue exceeded the $21.72 million consensus estimate, although the company still posted a larger-than-expected quarterly loss. The average analyst price target is approximately $10.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating little measurable short-selling pressure, but also providing limited incremental trading information.
• Negative Sentiment: Several insiders recently sold shares: CTO Abhimanyu Verma sold 5,000 shares on August 19 and another 5,000 on August 24; Director Kathy L. Hibbs sold 6,250 shares on August 25; and Philippe Menu sold 5,000 shares on August 25. The transactions reduced their individual holdings by roughly 2% to 6% and could weigh on sentiment. However, all were executed under pre-arranged Rule 10b5-1 plans, meaning they may not represent current concerns about SOPHiA GENETICS. SEC insider transaction filing
• Negative Sentiment: SOPHiA GENETICS remains unprofitable: it reported a quarterly loss of $0.26 per share versus the $0.21 consensus loss estimate, and analysts expect a full-year loss of approximately $0.77 per share. Its negative margins and continued earnings losses remain key risks despite the revenue beat and improving share-price momentum.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SOPH shares. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.